Properties, structure and stability of V(IV) hydrazide Schiff base ligand complex

Vanadium Complexes with Thioanilide Derivatives of Amino Acids: Inhibition of Human Phosphatases and Specificity in Various Cell Models of Metabolic Disturbances

In the text, the synthesis and characteristics of the novel ONS-type vanadium (V) complexes with thioanilide derivatives of amino acids are described. They showed the inhibition of human protein tyrosine phosphatases (PTP1B, LAR, SHP1, and SHP2) in the submicromolar range, as well as the inhibition of non-tyrosine phosphatases (CDC25A and PPA2) similar to bis(maltolato)oxidovanadium(IV) (BMOV). The ONS complexes increased [14C]-deoxy-D-glucose transport into C2C12 myocytes, and one of them, VC070, also enhanced this transport in 3T3-L1 adipocytes. These complexes inhibited gluconeogenesis in hepatocytes HepG2, but none of them decreased lipid accumulation in the non-alcoholic fatty liver disease model using the same cells. Compared to the tested ONO-type vanadium complexes with 5-bromosalicylaldehyde and substituted benzhydrazides as Schiff base ligand components, the ONS complexes revealed stronger inhibition of protein tyrosine phosphatases, but the ONO complexes showed greater activity in the cell models in general. Moreover, the majority of the active complexes from both groups showed better effects than VOSO4 and BMOV. Complexes from both groups activated AKT and ERK signaling pathways in hepatocytes to a comparable extent. One of the ONO complexes, VC068, showed activity in all of the above models, including also glucose utilizatiand ONO Complexes are Inhibitors ofon in the myocytes and glucose transport in insulin-resistant hepatocytes. The discussion section explicates the results within the wider scope of the knowledge about vanadium complexes.

Asymmetric dinuclear, hexanuclear and octanuclear oxovanadium citrates with triazolates: novel mixed-ligands and mixed-valence complexes

The triazolate-assisted asymmetric dinuclear oxovanadium(IV) citrate [V2O2(cit)(Hdatrz)3]·5H2O (1, H4cit = citric acid, Hdatrz = 1H-1,2,4-triazole-3,5-diamine) and its additive salt [V2O2(cit)(Hdatrz)3][V2O2(cit)2]½·2H2datrz·9.5H2O (2) and the polymerized hexanuclear product [V6O6(μ3-O)2(cit)2(Hdatrz)4]·4H2O (3) have been isolated at different temperatures, respectively. Adduct 2 shows strong evidence for the conversion of a symmetric dinuclear oxovanadium(IV) citrate to a mixed-ligand asymmetric oxovanadium(IV) citrate. Moreover, a fully oxidized trinuclear vanadium(V) species [V3O6(μ2-OH)(μ3-O)(Hdatrz)2]·4.5H2O (4) has also been isolated as a quasi-intermediate product of 3 without the coordination of citrate. Intriguingly, an octanuclear mixed-valence oxovanadium(V/IV) citrate K2{[VIV/V2O2(cit)(Hdatrz)(datrz)]2[VIV2O2(cit)(Hdatrz)(datrz)]2}·27.5H2O (5) has been obtained with different vanadium units, where dinuclear mixed-ligands and mixed-valence oxovanadium(IV/V) citrates [VIV/V2O2(cit)(Hdatrz)(datrz)] (5a) and [VIV2O2(cit)(Hdatrz)(datrz)] (5b) have been trapped. Citrate adopts a μ2-η1:η1:η1:η2 coordination mode in 1, 2 and 5, while a μ3-η1:η1:η1:η2 fashion has been observed in 3. Unlike 1-4, complex 5 contains both protonated and deprotonated triazolates simultaneously, where four triazolates further coordinate in a μ3-η1:η1:η1 manner to construct an octanuclear unit. These different structural features in 1-5 are dominated by flexible multidentate citrates and protonated/deprotonated triazolates, showing their synergistic effects. Furthermore, 1 exhibits a rectangular channel, showing preferential adsorption of O2 and CO2 over gases N2, H2, and CH4.

Vanadium(IV) complexes of salicylaldehyde-based furoic acid hydrazones: Synthesis, BSA binding and in vivo antidiabetic potential

Solution synthesis afforded five novel neutral heteroleptic octahedral paramagnetic mononuclear oxidovanadium(IV) complexes of general composition [VO(bpy)L], where L is a dianionic tridentate ONO-donor hydrazone ligand derived from 2-furoic acid hydrazide and salicylaldehyde and its 5-substituted derivatives. Characterization was carried out by elemental analysis, mass spectrometry, infrared, electron, NMR, and EPR spectroscopy, cyclic voltammetry and conductometry. The molecular and crystal structure of the complex with 5-chloro-salicylaldehyde 2-furoic acid hydrazone (2) was determined. The quantum chemical properties of the vanadium complexes were studied at B3LYP and M062X levels with the lanl2dz basis set using Gaussian. Additionally, Swiss-ADME analysis was performed and complex (4), featuring a 5-nitro substituent on the hydrazone ligand, was selected for further investigation. The effects of the in vivo application of the complex on selected biochemical parameters in healthy and diabetic Wistar rats were investigated. Strong antidiabetic effect associated with moderate hypoalbuminemia was observed. Furthermore, the interaction of complexes with BSA was studied by spectrofluorimetry. A significant conformational change of BSA in the presence of vanadium complexes was found. Synchronous fluorescence spectra revealed significant changes in the tyrosine microenvironment of BSA. The FRET analysis was also used and the non-radiative process of energy transfer is elucidated. Thermodynamic data suggest van der Waals forces and hydrogen bonding as predominant binding modes of complexes to BSA.

Ionic Dioxidovanadium(V) Complexes with Schiff-Base Ligands as Potential Insulin-Mimetic Agents-Substituent Effect on Structure and Stability

Four dioxidovanadium(V) complexes with Schiff-base ligands based on 2-hydroxybenzhydrazide with four different substituted salicylaldehydes (5-chlorosalicylaldehyde, 3,5-dichlorosalicylaldehyde, 5-nitrosalicylaldehyde, 3-bromo-5-chlorosalicylaldehyde) were synthesized and described, by using V₂O₅ and triethylamine. The single crystal X-ray structure measurements as well as elemental analyses and IR spectra confirmed the formulas of the ionic complexes with a protonated triethylamine acting as counterion, HTEA[VO₂(L)] (HL = Schiff-base ligand). The kinetic stability of the complexes at pH = 2 and 7 was discussed with respect to the neutral vanadium(V) complexes previously studied as potential insulin-mimetic agents. A correlation between the substituents in an aromatic ring of the Schiff-base ligands with crystal packing, and also with the stability of the compounds, was presented.

Electrochemically Induced Phase Transition in V3 O7 · H2 O Nanobelts/Reduced Graphene Oxide Composites for Aqueous Zinc-Ion Batteries

V₃ O₇ ·H₂ O nanobelts/reduced graphene oxide (rGO) composites (weight ratio: 86%/14%) are synthesized by a microwave approach with a high yield (85%) through controlling pH with acids. The growth mechanisms of the highly crystalline nanobelts (average diameter: 25 nm; length: ≈20 µm; oriented along the [101] direction) have been thoroughly investigated, with the governing role of the acid upon the morphology and oxidation state of vanadium disclosed. When used as the ZIB cathode, the composite can deliver a high specific capacity of 410.7 and 385.7 mAh g^-1 at the current density of 0.5 and 4 A g^-1 , respectively, with a high retention of the capacity of 93%. The capacity of the composite is greater than those of V₃ O₇  · H₂ O, V₂ O₅ nanobelts, and V₅ O₁₂  · 6H₂ O film. Zinc ion storage in V₃ O₇ ·H₂ O/rGO is mainly a pseudocapacitive behavior rather than ion diffusion. The presence of rGO enables outstanding cycling stability of up to 1000 cycles with a capacity retention of 99.6%. Extended cycling shows a gradual phase transition, that is, from the original orthorhombic V₃ O₇  · H₂ O to a stable hexagonal Zn₃ (VO₄ )₂ (H₂ O)_2.93 phase, which is a new electrochemical route found in V₃ O₇ materials. This phase transition process provides new insight into the reactions of aqueous ZIBs.

Synthesis, Characterization, and In Vitro Insulin-Mimetic Activity Evaluation of Valine Schiff Base Coordination Compounds of Oxidovanadium(V)

Type 2 diabetes became an alarming global health issue since the existing drugs do not prevent its progression. Herein, we aimed to synthesize and characterize a family of oxidovanadium(V) complexes with Schiff base ligands derived from L-/D-valine (val) and salicylaldehyde (sal) or o-vanillin (van) as insulin-mimetic agents and to assess their potential anti-diabetic properties. Two new oxidovanadium(V) complexes, [{VVO(R-salval)(H2O)}(μ2-O){VVO(R-salval)}] and [{VVO(R-vanval)(CH3OH)}2(μ2-O)], and their S-enantiomers were synthesized and characterized. The compounds exhibit optical activity as shown by crystallographic and spectroscopic data. The stability, the capacity to bind bovine serum albumin (BSA), the cytotoxicity against human hepatoma cell line, as well as the potential anti-diabetic activity of the four compounds are investigated. The synthesized compounds are stable for up to three hours in physiological conditions and exhibit a high capacity of binding to BSA. Furthermore, the synthesized compounds display cytocompatibility at biologically relevant concentrations, exert anti-diabetic potential and insulin-mimetic activities by inhibiting the α-amylase and protein tyrosine phosphatase activity, and a long-term increase of insulin receptor phosphorylation compared to the insulin hormone. Thus, the in vitro anti-diabetic potential and insulin-mimetic properties of the newly synthesized oxidovanadium(V) compounds, correlated with their cytocompatibility, make them promising candidates for further investigation as anti-diabetic drugs.

Characterization and antidiabetic activity of salicylhydrazone Schiff base vanadium(IV) and (V) complexes

Twenty-four oxidovanadium(IV,V) complexes with tridentate Schiff base ligands based on 5-nitrosalicylaldehyde, 5-methoxysalicylaldehyde, or 5-sulfosalicylaldehyde and respective hydrazide were isolated, and characterized using physicochemical and spectroscopic methods. Three of them were structurally characterized by single-crystal X-ray structure determination. The biological activity studies included inhibition of human tyrosine phosphatases, studies on myocyte C2C12, adipocyte 3T3-L1, and human hepatocyte HepG2 cell lines, glucose uptake in myocytes and adipocytes, and cytotoxicity tests. The complexes that were unstable in solutions showed biological activity typical of other V(IV) complexes, while the stable one showed much higher, ligand-dependent, activity.

Naphthoylhydrazones: coordination to metal ions and biological screening

V^IVO, Cu^II and Zn^II complexes from three new naphthoylhydrazones were screened towards their ability to bind albumin and their cytotoxicity.